|会社名||Aptevo Therapeutics Inc （アプテボ・セラピュ―ティクス）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 アプテボ・セラピューティクス(Aptevo Therapeutics Inc.)はバイオ技術会社である。同社は患者の生命を管理するためにオンコロジー（がん）及び血液学（血液疾患）治療薬の生産に従事する。同社の事業はオンコロジー及び血液学治療薬の発見・開発・商品化・販売を行う。核心技術はADAPTIS(モジュラータンパク質技術)プラットフォームである。同社は血液学と感染症分野で約4つの製品を有し、並びに免疫腫瘍学における多様な治験段階の製品候補を有する。その治験段階の製品候補であるMOR209/ES414、ES210、ES425及びotlertuzumabはADAPTISプラットフォーム上に構築される。同社の販売製品は｢WinRho SDF｣(抗 D(Rho)ヒト免疫グロブリン)、｢HepaGam B｣(B型肝炎ヒト免疫グロブリン)、｢VARIZIG｣(水痘帯状疱疹ヒト免疫グロブリン)及び｢IXINITY｣(血液凝固第IX因子(組換え型))である。 アプテボ・セラピュ―ティクスは米国のバイオ医薬品企業。主にがんと血液疾患に対し、同社開発のモジュラ―・タンパク質技術「ADAPTIR」による治療に従事する。がん治療、免疫療法に利用される候補薬に「MOR209/ES414」、「ES210」、「ES425」、「Otlertuzumab」などを含む。本社はワシントン州シアトル。 Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR™ platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer.|
|本社所在地||2401 4th Avenue Suite 1050 Seattle WA 98121 USA|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Aptevo Therapeutics Inc revenues increased 92% to $10.9M. Net loss before extraordinary items increased 5% to $27.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 52% to $17.4M (expense) Other expense from continuing operations increase of 22% to $1.1M (expense).|
Why Are Aptevo Therapeutics Shares Trading Higher Today? 2022/02/09 19:28:22 Benzinga
Aptevo Therapeutics Inc (NASDAQ: APVO ) earned a $10 million non-dilutive milestone payment related to 2021 sales of Ruxience, under the terms of its royalty purchase agreement with HealthCare Royalty Management LLC . Additionally, the Company is optimistic about the possibility of earning additional milestones totaling $22.5 million over the next two years. The Company Full story available on Benzinga.com
40 Stocks Moving In Wednesday''s Mid-Day Session 2022/02/09 17:11:19 Benzinga
Gainers US Ecology, Inc. (NASDAQ: ECOL ) shares jumped 68.1% to $47.34 after Republic Services reported it will buy the company at $48 per share in cash. Tritium DCFC Limited (NASDAQ: DCFC ) gained 65.4% to $15.78. Tritium DCFC shares surged nearly 40% Tuesday after the Australian EV charging company announced its new manufacturing facility will be located in the United States. Tritium CEO Jane Hunter appeared at the White House to make the announcement yesterday. Infobird Co., Ltd (NASDAQ: IFBD ) gained 32.6% to $1.2393. Infobird recently signed a contract with subsidiary of Nippi Japan for digital marketing solutions. Doximity, Inc. (NYSE: DOCS ) shares gained 25.1% to $62.30 after the company reported better-than-expected Q3 results and issued FY22 sales guidance above estimates. Aptevo Therapeutics Inc. (NASDAQ: APVO ) jumped 20.5% to $7.29 after the company announced it has earned a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE. Absolute Software Corporation (NASDAQ: ABST ) gained 17.9% to $9.47 after the company reported better-than-expected Q2 sales results and issued FY22 sales guidance.
Doximity, Aptevo top healthcare gainers; Varex Imaging, BioCardia among losers 2022/02/09 15:02:30 Seeking Alpha
Doximity DOCS +20%. Aptevo Therapeutics APVO +17%. Varex Imaging (VREX) -11%. BioCardia (BCDA) -8%.
Aptevo Therapeutics receives $10M in non-dilutive milestone payment on RUXIENCE sales 2022/02/09 13:57:14 Seeking Alpha
Aptevo Therapeutics (APVO) trades 5.8% higher premarket after the company earned $10M non-dilutive milestone payment related to 2021 sales of RUXIENCE; this is under its royalty
Aptevo Therapeutics (NASDAQ:APVO) Rating Lowered to Neutral at UBS Group 2021/12/24 06:32:41 Dakota Financial News
Aptevo Therapeutics (NASDAQ:APVO) was downgraded by investment analysts at UBS Group from a buy rating to a neutral rating in a report issued on Wednesday, The Fly reports. Several other brokerages also recently commented on APVO. Roth Capital lowered their target price on Aptevo Therapeutics from $50.00 to $36.00 and set a buy rating for 
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index - Stocks News Feed 2021/06/29 12:38:41 Stocks News Feed
SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. (Aptevo) (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies today announced that the company has been added to the Russell Microcap® Index at the conclusion of the 2021 annual reconstitution. Aptevos Read More »Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
Aptevo Therapeutics Announces Inclusion in the Russell Microcap Index 2021/06/29 12:08:00 FinanzNachrichten
SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based o
Aptevo CEO says Seattle biotech scene is ''robust and growing'' 2021/06/26 03:00:00 Business Journals
Aptevo Therapeutics is a small, passion-driven biotech company that, I am proud to say, lives its principles, CEO Marvin White said. Its our biggest strength and motivates us as individuals and as a team.
Aptevo Therapeutics Insights: Return On Capital Employed 2021/06/18 14:22:21 Benzinga
In Q1, Aptevo Therapeutics (NASDAQ: APVO ) posted sales of $2.42 million. Earnings were up 1.01%, but Aptevo Therapeutics still reported an overall loss of $6.89 million. In Q4, Aptevo Therapeutics brought in $2.37 million in sales but lost $6.82 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful Full story available on Benzinga.com
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial 2021/01/11 13:00:00 Yahoo Finance
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.
Global Bi Syndrome Treatment Market 2020:Quantitative Analysis By Aptevo THERAPEUTICS INC., OncoMed Pharmaceuticals, Inc., Roche, MacroGenics, Inc., AbbVie Inc., Regeneron Pharmaceuticals, Inc., Xencor 2020/11/20 13:21:04 OpenPR
This Bi Syndrome Treatment report provides complete analysis of the market on global and regional level. It inspects the development rate and the market value dependent on the market elements and growth initiating factors. The market players
APVO Gets Buyout Offer, PFE/BNTX' COVID Shot 95% Effective, CORT Gets Favorable PTAB Ruling 2020/11/19 02:13:00 RTT News
Today's Daily Dose brings you news about the buyout offer received by Aptevo, updated efficacy data of Pfizer/BioNTech's COVID-19 vaccine candidate, Corcept receiving a favorable ruling from Patent Trial & Appeal Board related to the U.
80 Biggest Movers From Yesterday 2020/11/11 10:01:48 Benzinga
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC ) shares surged 120.5% to close at $5.16 on Tuesday after the company reported it will begin offering integrated electric drivetrain system to existing forklift OEM clientele to support manufacture of electric forklifts using lithium batteries. Summit Wireless Technologies, Inc. (NASDAQ: WISA ) rose 70.4% to close at $3.63 after the company reported 45% year-over-year revenue growth for the third quarter. The company also said it sees more than 100% year-over-year revenue growth for Q4. Revlon, Inc. (NYSE: REV ) gained 47.2% to close at $8.79. Trxade Group, Inc. (NASDAQ: MEDS ) shares rose 41.9% to close at $6.10 after the company entered into a solution marketing program agreement with Amazon.com Services, LLC to promote Amazon storage lockers. Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) climbed 35.4% to close at $11.51 after the company posted a profit for the third quarter. Aptevo Therapeutics Inc. (NASDAQ: APVO ) gained 35.4% to close at $44.32.
Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update - Stocks News Feed 2020/11/10 22:39:57 Stocks News Feed
$1.5 million of RUXIENCE® Royalties Earned in the Third Quarter Funding Extends Cash Runway Into Q3 2021 SEATTLE, WA / ACCESSWIRE / November 10, 2020 / Aptevo Therapeutics Inc. (“Aptevo” or “the Company”) (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today reported financial results… Read More »Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 アプテボ・セラピュ―ティクス APVO Aptevo Therapeutics Inc.）